Compare Citius Pharmaceuticals Inc (CTXR) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.71 (market cap $20.01M), while Vanguard Total Stock Market Index Fund ETF trades at $381.97. The key difference: Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | VTI | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | — |
52-Week High | $1.82 | $381.78 |
52-Week Low | $0.48 | $311.68 |
Enterprise Value | $16.23M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
VTI trades at $381.85, up 0.06% with a bullish technical signal from moving averages. The ETF maintains broad diversification across 3,500+ US stocks with a low 0.03% expense ratio. Recent institutional activity shows mixed positioning with some firms increasing holdings while others reduced exposure.
The outlook remains positive given VTI's role as a core total market holding, though the elevated RSI suggests potential near-term consolidation. Key risks include market concentration in large-cap tech and broader economic volatility affecting overall equity performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
